Difference between revisions of "Crizanlizumab (Adakveo)"
Jump to navigation
Jump to search
m (Jwarner moved page Crizanlizumab (SEG101) to Crizanlizumab (Adakveo): FDA approval) |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Definition from the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=788634 NCI Drug Dictionary]: A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells. | Definition from the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=788634 NCI Drug Dictionary]: A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells. | ||
| − | = | + | ==Diseases for which it is used== |
| − | ==[[Sickle cell anemia]]== | + | *[[Sickle cell anemia]] |
| − | * | + | |
| + | ==History of changes in FDA indication== | ||
| + | *11/15/2019: Approved to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with [[Sickle cell anemia|sickle cell disease]]. | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' SEG101 | ||
| + | *'''Generic name:''' crizanlizumab-tmca | ||
| + | *'''Brand name:''' Adakveo | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 11: | Line 18: | ||
[[Category:Anti-P-selectin antibodies]] | [[Category:Anti-P-selectin antibodies]] | ||
| − | [[Category: | + | [[Category:Sickle cell anemia medications]] |
| + | |||
| + | [[Category:FDA approved in 2019]] | ||
Revision as of 22:04, 21 November 2019
Mechanism of action
Definition from the NCI Drug Dictionary: A humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. Upon administration, crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand-1 (PSGL-1; SELPLG) on neutrophils and monocytes. P-selectin, a glycoprotein that functions as a cell adhesion molecule (CAM), translocates to the surface of activated endothelial cells and platelets, upon stimulation, where it binds to its ligand and mediates the rolling of platelets and neutrophils on activated endothelial cells.
Diseases for which it is used
History of changes in FDA indication
- 11/15/2019: Approved to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.
Also known as
- Code name: SEG101
- Generic name: crizanlizumab-tmca
- Brand name: Adakveo